Biomedicine & Pharmacotherapy,
Journal Year:
2023,
Volume and Issue:
170, P. 116001 - 116001
Published: Dec. 20, 2023
Intervertebral
disc
degeneration
(IVDD)
is
a
main
cause
of
low
back
pain
(LBP),
which
can
lead
to
disability
and
thus
generate
heavy
burden
on
society.
IVDD
characterized
by
decrease
in
nucleus
pulposus
cells
(NPCs)
endogenous
mesenchymal
stem
(MSCs),
degradation
the
extracellular
matrix,
macrophage
infiltration,
blood
vessel
nerve
ingrowth.
To
date,
therapeutic
approaches
regarding
mainly
include
conservative
treatment
surgical
intervention.
However,
both
only
relieve
symptoms
rather
than
stop
or
revert
progression
IVDD,
since
pathogenesis
not
yet
clear.
Pyroptosis,
Caspase
family
dependence
conducted
Gasdermin
family,
newly
discovered
mode
programmed
cell
death.
Pyroptosis
has
been
observed
NPCs,
annulus
fibrosus
(AFCs),
chondrocytes,
MSCs,
macrophages,
vascular
endothelial
neurons
may
contribute
IVDD.
MSCs
are
kind
pluripotent
that
be
found
almost
all
tissues.
have
strong
ability
secrete
vesicles
(EVs),
contain
exosomes,
microvesicles
apoptotic
bodies.
EVs
derived
from
play
an
important
role
pyroptosis
regulation
could
beneficial
for
alleviating
This
review
focuses
clarifying
improve
MSCs.
Signal Transduction and Targeted Therapy,
Journal Year:
2024,
Volume and Issue:
9(1)
Published: Jan. 12, 2024
Abstract
Although
stem
cell-based
therapy
has
demonstrated
considerable
potential
to
manage
certain
diseases
more
successfully
than
conventional
surgery,
it
nevertheless
comes
with
inescapable
drawbacks
that
might
limit
its
clinical
translation.
Compared
cells,
cell-derived
exosomes
possess
numerous
advantages,
such
as
non-immunogenicity,
non-infusion
toxicity,
easy
access,
effortless
preservation,
and
freedom
from
tumorigenic
ethical
issues.
Exosomes
can
inherit
similar
therapeutic
effects
their
parental
cells
embryonic
adult
through
vertical
delivery
of
pluripotency
or
multipotency.
After
a
thorough
search
meticulous
dissection
relevant
literature
the
last
five
years,
we
present
this
comprehensive,
up-to-date,
specialty-specific
disease-oriented
review
highlight
surgical
application
exosomes.
derived
(e.g.,
embryonic,
induced
pluripotent,
hematopoietic,
mesenchymal,
neural,
endothelial
cells)
are
capable
treating
encountered
in
orthopedic
neurosurgery,
plastic
general
cardiothoracic
urology,
head
neck
ophthalmology,
obstetrics
gynecology.
The
diverse
cells-derived
hierarchical
translation
tissue-specific
responses,
cell-specific
molecular
signaling
pathways.
In
review,
viable
potent
alternative
managing
various
conditions.
We
recommend
future
research
combines
wisdoms
surgeons,
nanomedicine
practitioners,
cell
researchers
intriguing
area.
Stem Cell Research & Therapy,
Journal Year:
2024,
Volume and Issue:
15(1)
Published: March 27, 2024
Abstract
Musculoskeletal
disorders
are
the
leading
causes
of
physical
disabilities
worldwide.
The
poor
self-repair
capacity
musculoskeletal
tissues
and
absence
effective
therapies
have
driven
development
novel
bioengineering-based
therapeutic
approaches.
Adipose-derived
stem
cell
(ADSC)-based
being
explored
as
new
regenerative
strategies
for
repair
regeneration
bone,
cartilage,
tendon
owing
to
accessibility,
multipotency,
active
paracrine
activity
ADSCs.
In
this
review,
recent
advances
in
ADSCs
their
optimization
strategies,
including
ADSC-derived
exosomes
(ADSC-Exos),
biomaterials,
genetic
modifications,
summarized.
Furthermore,
preclinical
clinical
applications
ADSC-Exos,
either
alone
or
combination
with
growth
factors
biomaterials
genetically
modified
forms,
reviewed.
ADSC-based
hold
promise
management
multiple
types
injuries.
timely
summary
highlights
provided
here
could
offer
guidance
further
investigations
accelerate
application
regeneration.
Graphical
abstract
Science Advances,
Journal Year:
2024,
Volume and Issue:
10(7)
Published: Feb. 14, 2024
Osteoarthritis
(OA)
is
characterized
by
cartilage
damage,
inflammation,
and
pain.
Vascular
endothelial
growth
factor
receptors
(VEGFRs)
have
been
associated
with
OA
severity,
suggesting
that
inhibitors
targeting
these
alleviate
pain
(via
VEGFR1)
or
degeneration
VEGFR2).
We
developed
a
nanoparticle-based
formulation
of
pazopanib
(Votrient),
an
FDA-approved
anticancer
drug
targets
both
VEGFR1
VEGFR2
(Nano-PAZII).
demonstrate
single
intraarticular
injection
Nano-PAZII
can
effectively
reduce
joint
for
prolonged
time
without
substantial
side
effects
in
two
different
preclinical
rodent
models
involving
either
surgical
(upon
partial
medial
meniscectomy)
nonsurgical
induction
(with
monoiodoacetate).
The
blocks
relieves
suppressing
sensory
neuronal
ingrowth
into
the
knee
synovium
plasticity
dorsal
root
ganglia
spinal
cord.
Simultaneously,
inhibition
reduces
degeneration.
These
findings
provide
mechanism-based
disease-modifying
strategy
addresses
symptoms
loss
OA.
Bone Research,
Journal Year:
2025,
Volume and Issue:
13(1)
Published: March 17, 2025
Abstract
Following
the
discovery
of
bone
as
an
endocrine
organ
with
systemic
influence,
bone-brain
interaction
has
emerged
a
research
hotspot,
unveiling
complex
bidirectional
communication
between
and
brain.
Studies
indicate
that
brain
can
influence
each
other’s
homeostasis
via
multiple
pathways,
yet
there
is
dearth
systematic
reviews
in
this
area.
This
review
comprehensively
examines
interactions
across
three
key
areas:
bone-derived
factors
on
function,
effects
brain-related
diseases
or
injuries
(BRDI)
health,
concept
skeletal
interoception.
Additionally,
discusses
innovative
approaches
biomaterial
design
inspired
by
mechanisms,
aiming
to
facilitate
through
materiobiological
aid
treatment
neurodegenerative
bone-related
diseases.
Notably,
integration
artificial
intelligence
(AI)
highlighted,
showcasing
AI’s
role
expediting
formulation
effective
targeted
strategies.
In
conclusion,
offers
vital
insights
into
mechanisms
suggests
advanced
harness
these
clinical
practice.
These
offer
promising
avenues
for
preventing
treating
impacting
skeleton
brain,
underscoring
potential
interdisciplinary
enhancing
human
health.
Journal of Pain Research,
Journal Year:
2024,
Volume and Issue:
Volume 17, P. 1171 - 1182
Published: March 1, 2024
Abstract:
Specific
clinical
diagnostic
criteria
have
established
a
consensus
for
defining
patients
with
lumbar
discogenic
pain.
However,
if
conservative
medical
management
fails,
these
few
treatment
options
short
of
surgery
involving
discectomy
often
coupled
fusion
or
arthroplasty.
There
is
rapidly-emerging
research
effort
to
fill
this
gap
intradiscal
therapies
that
can
be
delivered
minimally-invasively
via
fluoroscopically
guided
injection
without
altering
the
normal
anatomy
affected
vertebral
motion
segment.
Viable
candidate
products
date
included
mesenchymal
stromal
cells,
platelet-rich
plasma,
nucleus
pulposus
structural
allograft,
and
other
cell-based
compositions.
The
objective
repair,
supplement,
restore
damaged
intervertebral
disc
as
well
retard
further
degeneration.
In
doing
so,
intervention
meant
eliminate
source
pain
avoid
surgery.
Methodologically
rigorous
studies
are
rare,
however,
based
on
best
evidence,
safety
magnitude
duration
efficacy
remain
difficult
estimate.
Further,
we
summarize
US
Food
Drug
Administration's
(FDA)
guidance
regarding
interpretation
minimal
manipulation
homologous
use
criteria,
which
central
designating
tissue
drug/device/biologic.
We
also
provide
perspectives
core
evidence
knowledge
gaps
associated
therapies,
propose
imperatives
evaluating
effectiveness
treatments
highlight
several
new
technologies
horizon.
Keywords:
degenerative,
disc,
intradiscal,
autologous,
allogeneic,
injection,
regenerative,
discogenic,
Intervertebral
disc
degeneration
(IVDD)
is
a
prevalent
cause
of
low
back
pain
and
leading
contributor
to
disability.
IVDD
progression
involves
pathological
shifts
marked
by
low-grade
inflammation,
extracellular
matrix
remodeling,
metabolic
disruptions
characterized
heightened
glycolytic
pathways,
mitochondrial
dysfunction,
cellular
senescence.
Extensive
posttranslational
modifications
proteins
within
nucleus
pulposus
cells
chondrocytes
play
crucial
roles
in
reshaping
the
intervertebral
phenotype
orchestrating
metabolism
inflammation
diverse
contexts.
This
review
focuses
on
pivotal
phosphorylation,
ubiquitination,
acetylation,
glycosylation,
methylation,
lactylation
pathogenesis.
It
integrates
latest
insights
into
various
modification-mediated
inflammatory
signaling
networks,
laying
groundwork
for
targeted
proteomics
metabolomics
treatment.
The
discussion
also
highlights
unexplored
territories,
emphasizing
need
future
research,
particularly
understanding
role
health,
an
area
currently
shrouded
mystery.
